Raytheon awarded $71 million in Navy contracts for missile systems
NEW YORK - Olaplex Holdings, Inc. (NASDAQ:OLPX) announced Tuesday it has acquired Boston-based biotech company Purvala Bioscience, marking the haircare brand’s first acquisition since its launch over ten years ago.
Purvala, founded in 2020 by Drs. Bradley Olsen, Justin Paloni, and colleagues, develops bioinspired technologies with applications across health and beauty industries. Dr. Olsen also serves as a Professor of Chemical Engineering at MIT.
The acquisition aims to enhance Olaplex’s product innovation capabilities alongside its existing bond-building technology. The financial terms of the transaction were not disclosed in the press release.
"Since the very beginning, OLAPLEX was founded on the concept of innovation with groundbreaking bond technology that empowered stylists and their clients to achieve transformative results," said Olaplex CEO Amanda Baldwin in the announcement.
Olaplex, which went public in 2021, is known for its hair care products featuring bond-building technology that works by protecting, strengthening, and relinking bonds during and after hair services. The company maintains impressive gross profit margins of 71% and currently trades at a market capitalization of approximately $941 million. According to InvestingPro data, the stock has shown significant momentum with a 12% return over the past week.
The company stated it believes the acquisition will help create "the next generation of disruptive science-backed product innovation" to complement its patent-protected bond-building technology. While Olaplex currently operates with a moderate debt level and maintains strong liquidity with a current ratio of 3.86, InvestingPro analysis indicates the company appears undervalued based on its Fair Value assessment. Analysts expect the company to return to profitability this year, with 12 additional ProTips available for subscribers.
Purvala has focused on creating high-performing molecules inspired by naturally occurring biological structures since its inception five years ago.
Olaplex products are sold globally through professional, specialty retail, and direct-to-consumer channels.
The information in this article is based on a press release statement from Olaplex Holdings, Inc. For a comprehensive analysis of Olaplex’s financial health, growth prospects, and detailed valuation metrics, access the full Pro Research Report available exclusively on InvestingPro, covering over 1,400 top US stocks.
In other recent news, Olaplex Holdings reported its second-quarter 2025 earnings, showing a mixed performance. The company’s earnings per share (EPS) came in at -$0.0048, missing the forecast of $0.0128, a surprise shortfall of 137.5%. However, Olaplex’s revenue for the quarter was $106.3 million, exceeding the expected $100.64 million by 5.6% and marking a 2.3% year-over-year increase. This revenue growth was the first positive sales growth for Olaplex in nine quarters, surpassing both Canaccord Genuity’s and Wall Street’s projections, which had anticipated sales declines.
Additionally, Canaccord Genuity upgraded Olaplex from Hold to Buy, citing brand reinvigoration and a potential return to growth, and raised its price target to $2.00 from $1.50. This upgrade reflects a notable shift in sentiment, as Canaccord Genuity had previously lowered its price target to $1.50 due to margin pressures. The upgrade makes Susan Anderson of Canaccord Genuity the sole bullish analyst among nine firms covering Olaplex. Despite the challenges, these developments indicate a cautiously optimistic outlook for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.